TickerFacts.

A business in context

ACAD research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-08-05 · 0001899977-26-000008

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-333243

  3. 8-K · Current report

    Report date 2026-08-04 · 0001193125-26-332858 · Items 2.02,9.01

  4. 4 · Ownership change

    Report date 2026-07-29 · 0001861477-26-000005

  5. 4 · Ownership change

    Report date 2026-06-26 · 0001816160-26-000009

  6. 4 · Ownership change

    Report date 2026-05-29 · 0001193125-26-253632

  7. 4 · Ownership change

    Report date 2026-05-29 · 0001865210-26-000002

  8. 4 · Ownership change

    Report date 2026-05-29 · 0001826361-26-000002

  9. 4 · Ownership change

    Report date 2026-05-29 · 0001604689-26-000009

  10. 4 · Ownership change

    Report date 2026-05-29 · 0001560782-26-000002

  11. 8-K · Current report

    Report date 2026-05-29 · 0001193125-26-248242 · Items 5.02,5.07,9.01

  12. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-209731

  13. 8-K · Current report

    Report date 2026-05-06 · 0001193125-26-209253 · Items 2.02,9.01

  14. 8-K · Current report

    Report date 2026-04-27 · 0001193125-26-197957 · Items 5.02,7.01,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-05-29 · 0001193125-26-174163

  16. 8-K · Current report

    Report date 2026-03-03 · 0001193125-26-092213 · Items 5.02

  17. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-072519

  18. 8-K · Current report

    Report date 2026-02-25 · 0001193125-26-071674 · Items 2.02,9.01

  19. 8-K · Current report

    Report date 2026-01-13 · 0001193125-26-011706 · Items 2.02,7.01,9.01

  20. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-267453

  21. 8-K · Current report

    Report date 2025-11-05 · 0001193125-25-266959 · Items 2.02,9.01

  22. 8-K · Current report

    Report date 2025-10-28 · 0001193125-25-262610 · Items 5.02

  23. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-104295

  24. 8-K · Current report

    Report date 2025-08-06 · 0000950170-25-104092 · Items 2.02,9.01

  25. 8-K · Current report

    Report date 2025-06-09 · 0001193125-25-138452 · Items 8.01

  26. 8-K · Current report

    Report date 2025-05-29 · 0001193125-25-130620 · Items 5.07

  27. 8-K · Current report

    Report date 2025-05-15 · 0001193125-25-123175 · Items 1.01,8.01

  28. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-066231

  29. 8-K · Current report

    Report date 2025-05-07 · 0000950170-25-065672 · Items 2.02,9.01

  30. DEF 14A · Proxy statement

    Report date 2025-05-29 · 0000950170-25-058827

  31. 8-K · Current report

    Report date 2025-04-15 · 0001193125-25-082809 · Items 5.03,9.01

  32. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-029253

  33. 8-K · Current report

    Report date 2025-02-26 · 0000950170-25-027759 · Items 2.02,9.01

  34. 8-K · Current report

    Report date 2024-12-11 · 0001193125-24-275595 · Items 2.01

  35. 8-K · Current report

    Report date 2024-11-18 · 0001193125-24-262556 · Items 5.02

  36. SC 13G/A · Ownership disclosure

    0000902664-24-006501

  37. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-122513

  38. 8-K · Current report

    Report date 2024-11-06 · 0000950170-24-122322 · Items 2.02,9.01

  39. 8-K · Current report

    Report date 2024-09-17 · 0001193125-24-223726 · Items 5.02,9.01

  40. 10-Q · Quarterly report

    Report date 2024-06-30 · 0000950170-24-092163

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 6 transaction rows6SGrant / award: 16 transaction rows16AExercise / conversion: 20 transaction rows20MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

42 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-26
2026-06-29
Kihara James
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock11421.026.08
2026-05-29
2026-06-01
Ndu AdoraM · Exercise / conversion
Acquired
Common Stock8107.0—
2026-05-29
2026-06-01
Ndu AdoraM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
8107.00.0
2026-05-29
2026-06-01
Ndu AdoraA · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-29
2026-06-01
Ndu AdoraA · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-01
GAROFALO ELIZABETH A.M · Exercise / conversion
Acquired
Common Stock8107.0—
2026-05-29
2026-06-01
GAROFALO ELIZABETH A.A · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-29
2026-06-01
GAROFALO ELIZABETH A.M · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
8107.00.0
2026-05-29
2026-06-01
GAROFALO ELIZABETH A.A · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-01
Poole JonathanM · Exercise / conversion
Acquired
Common Stock2010.0—
2026-05-29
2026-06-01
Poole JonathanA · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-01
Poole JonathanA · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-29
2026-06-01
Poole JonathanM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
2010.00.0
2026-05-29
2026-06-01
Daly James MM · Exercise / conversion
Acquired
Common Stock8107.0—
2026-05-29
2026-06-01
Daly James MA · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-01
Daly James MM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
8107.00.0
2026-05-29
2026-06-01
Daly James MA · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-29
2026-06-01
Brege LauraM · Exercise / conversion
Acquired
Common Stock8107.0—
2026-05-29
2026-06-01
Brege LauraM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
8107.00.0
2026-05-29
2026-06-01
Brege LauraA · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-29
2026-06-01
Brege LauraA · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-02
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPA · Grant / award
Acquired
Common Stock18622.00.0
2026-05-29
2026-06-02
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPA · Grant / award
Acquired
Common Stock18622.00.0
2026-05-29
2026-06-02
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPA · Grant / award
Acquired
Non- Qualified Stock Option (right to buy)
Derivative security
32008.00.0
2026-05-29
2026-06-02
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPA · Grant / award
Acquired
Non- Qualified Stock Option (right to buy)
Derivative security
32008.00.0
2026-05-29
2026-06-01
HARRIGAN EDMUNDM · Exercise / conversion
Acquired
Common Stock8107.0—
2026-05-29
2026-06-01
HARRIGAN EDMUNDA · Grant / award
Acquired
Restricted Stock Units
Derivative security
9311.00.0
2026-05-29
2026-06-01
HARRIGAN EDMUNDM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
8107.00.0
2026-05-29
2026-06-01
HARRIGAN EDMUNDA · Grant / award
Acquired
Director Stock Options (Right to Buy)
Derivative security
16004.00.0
2026-05-26
2026-05-27
Kihara JamesS · Sale
Disposed
Common Stock5401.021.18
2026-05-04
2026-05-05
Schneyer Mark C.S · Sale
Disposed
Common Stock3506.021.79
2026-05-04
2026-05-05
Kihara JamesS · Sale
Disposed
Common Stock1332.021.79
2026-05-01
2026-05-05
Schneyer Mark C.M · Exercise / conversion
Acquired
Common Stock6815.0—
2026-05-01
2026-05-05
Schneyer Mark C.M · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
6815.00.0
2026-05-01
2026-05-05
Kihara JamesM · Exercise / conversion
Acquired
Common Stock2596.0—
2026-05-01
2026-05-05
Kihara JamesM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
2596.00.0
2026-04-07
2026-04-07
Schneyer Mark C.S · Sale
Disposed
Common Stock2709.022.2
2026-04-07
2026-04-07
Kihara JamesS · Sale
Disposed
Common Stock1030.022.2
2026-04-05
2026-04-07
Schneyer Mark C.M · Exercise / conversion
Acquired
Common Stock5276.0—
2026-04-05
2026-04-07
Schneyer Mark C.M · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
5276.00.0
2026-04-05
2026-04-07
Kihara JamesM · Exercise / conversion
Acquired
Common Stock2010.0—
2026-04-05
2026-04-07
Kihara JamesM · Exercise / conversion
Disposed
Restricted Stock Units
Derivative security
2010.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001070494ACADIA PHARMACEUTICALS INC

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Acadia Pharmaceuticals · alias · wikidata
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$957.80M$1.02B
2023-12-31$726.44M$796.04M
2022-12-31$517.24M$590.07M
2021-12-31$484.14M$596.51M
2020-12-31$441.75M$569.95M
2019-12-31$339.08M$442.85M
2018-12-31$223.81M$297.60M
2017-12-31$124.90M$170.14M

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗